Treating oligoprogression with SBRT improved progression-free survival in patients with lung cancer but not in those with breast cancer.
Hypofractionated radiotherapy produces similar long-term outcomes as conventionally fractionated radiotherapy in high-risk prostate cancer, a phase 3 study suggests.
Prophylactic radiotherapy of asymptomatic bone metastases can reduce skeletal-related events and improve survival in patients with solid tumors, a study suggests.
Delivery of radiation to the celiac plexus can decrease pain and opioid use among patients with pancreatic cancer, a phase 2 study suggests.
Durvalumab plus IMRT proved no more effective than cetuximab plus IMRT in patients with treatment-naïve, locoregionally advanced head and neck squamous cell carcinoma.
Adding stereotactic body radiation therapy to sorafenib improves survival outcomes in patients with advanced hepatocellular carcinoma, a phase 3 trial suggests.
A concurrent radiation boost produces comparable outcomes as a sequential boost in patients with high-risk breast cancer, a phase 3 study suggests.
Adding oral S-1 chemotherapy to radiotherapy can improve outcomes in elderly patients with inoperable esophageal squamous cell carcinoma.
Proton FLASH radiotherapy is feasible, safe, and provides pain relief for cancer patients with bone metastases, according to a first-in-human trial.
Response-adapted ultra-low-dose radiation therapy demonstrated efficacy and negligible toxicity in orbital indolent B-cell lymphoma.